Stoke Therapeutics公司宣布,计划在2026年第二季度完成150名患者的入组工作。这一关键里程碑将为后续临床研究奠定基础。公司预计,三期临床试验的数据结果将于2027年中期正式公布。这一时间表的推进,标志着公司在相关治疗领域的研发工作取得重要进展。
Stoke Therapeutics公司宣布,计划在2026年第二季度完成150名患者的入组工作。这一关键里程碑将为后续临床研究奠定基础。公司预计,三期临床试验的数据结果将于2027年中期正式公布。这一时间表的推进,标志着公司在相关治疗领域的研发工作取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.